TerminatedNot Applicable

Prevalence of SARS-CoV-2 Genome in Tears of Asymptomatic and Moderately Symptomatic COVID-19 Patients

Stopped: less covid testing

France534 participantsStarted 2021-01-19

Plain-language summary

To evaluate the prevalence of SARS-CoV-2 genome in patients with asymptomatic and moderately symptomatic COVID19.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients receiving diagnostic nasopharyngeal PCR for COVID-19 as part of the usual care * Age ≥ 18. * Information and signature of consent * Affiliated with a social security scheme or entitled Exclusion Criteria: * Refusal to participate in the study * Eye surgery less than 3 months old * Unable to give informed consent * No coverage through the health insurance system * Patient under judicial protection * Patient on AME

What they're measuring

presence of SARS-CoV-2 genome in tears

Timeframe: at the end of the study, an average of 1 year

Trial details

NCT IDNCT04654325

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-04-29

View on ClinicalTrials.gov More SARS-CoV-2 trials